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1. Introduction
  
 Breast cancer (BC) is one of the main causes of 
death in the world. In 2012, it caused around 8.2 
million deaths (Ferlay et al. 2015). BC is the most 
frequently diagnosed cancer and the leading cause 
of cancer death among females, accounting for 
23% of the total cancer cases and 14% of the cancer 
deaths (Tirona et al. 2010). Metastasis in BC is 
caused by deficient immunosurveillance, including 
impairment of Natural Killer (NK) cell maturation, 
low NK cell counts in peripheral blood mononuclear 
cells (PBMCs), significantly lower NK activity in 
patients with BC than in healthy individuals (Dewan 
et al. 2009), decreased cytotoxic function (Levy et al. 
2011; Hwang et al. 2012), NK abnormalities (Levy 
et al. 2011), poor tumor infiltrate (Albertsson et al. 
2003; Esendagli et al. 2008), low NK cell numbers in 
tumors due to their inefficient homing into malignant 
tissues (Levy et al. 2011), and defective expression of 
activating receptors such as NKG2D, overexpression 
of inhibitory receptors NKG2A, CD158a, CD158b 
(Levy et al. 2011).
 Immunotherapy using NK cells can be used to 
obtain the large and sufficient numbers of functional 
NK cells necessary for clinical therapy. The number, 
purity and state of NK cell proliferation and activation 
are key factors in immunotherapy (Cheng et al. 
2013). NK cells are known as necessary effectors in 
suppressing cancer proliferation (Kelly et al. 2003; 
Smyth et al. 2005). Once NK cells recognize target 
cells such as cancer cells, they form an immunological 
synapse, and the secretory granules fuse with the 
presynaptic membrane and release perforin (Prf) 
and granzyme (Gzm) into the synaptic cleft. Released 
Prf provides transmembrane pores on the target cell 
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and enables Gzm to diffuse into the cell. Gzm then 
initiates the apoptosis of the target cells, and the NK 
cells detach from the dying cells and can interact with 
other target cells to accomplish serial killing (Harada 
et al. 2017). Therefore, the focus of recent cancer 
therapy has been to promote and develop NK cells as 
drugs (Hwang et al. 2012), using NK effectors such as 
cytokines (Levy et al. 2011). This study was conducted 
to evaluate the effect of inducing Interleukin 15 (IL15) 
on NK cells toward the following: i) improvement of 
NK cell activating receptors (NKG2D), ii) inducement 
cytotoxic towards BC cells, iii) apoptotic inducer of NK 
cells, iv) apoptotic genes expression of BC cells, vii) 
morphology and density of MCF7 cells by transwell 
of NK and BC cells. 
2. Materials and Methods
2.1. Culturing Breast Cancer and NK Cells
Breast cancer (MCF7) cells (ATCC® HTB-22™) 
obtained from Aretha Medika Utama, Biomolecular 
and Biomedical Research Center, Bandung, Indonesia 
were cultured in RPMI 1640 (Gibco, 11875093) 
supplemented with 10% FBS (Gibco, 26140079) and 
1% antibiotic/antimycotic. Meanwhile, NK92 cells 
(ATCC® CRL-2407™) from Aretha Medika Utama, 
Biomolecular and Biomedical Research Center, 
Bandung, Indonesia were cultured in MEM-without 
nucleosides (Gibco, 12561056) supplemented with 
12.5% FBS, 12.5% Horse Serum (Gibco, 16050122), 
Sodium bicarbonate (Merck, 106329), Myo-inositol 
(Sigma Aldrich, 17508), Folic Acid (Sigma Aldrich, 
F8758), IL-2 (BioLegend, 589106), 2-Mercaptoethanol 
(Gibco, 1628448), and 1% antibiotic/antimycotic 
(Gibco, 1772653). Cell cultures were maintained in 
T-75 flasks, at 37°C, 5% CO2. Culture mediums were 
changed every three days and sub-cultured at 80% 
confluence (Widowati et al. 2018; Widowati et al. 
2019).
2.2. Determination of NKG2A and NKG2D 
Gene Expression
A suspension of NK92 cells (1 x 106 cells) were 
seeded onto T-25 Flask (TPP, 90026) and incubated for 
24 hours at 37°C, 5% CO2. Afterwards, the cells were 
induced by human recombinant IL15 (BioLegend, 
715902) to reach final concentration at 5 ng/ml and 
10 ng/ml and incubated for 24 hours at 37°C, 5% CO2. 
The RNA isolation of NK92 was performed according 
to the protocol of RNA Isolation Kit (Bio-Rad, 732-
6820). The concentration and purity of RNA of each 
sample was determined at 260/280 nm. The cDNA 
synthesis was performed using cDNA synthesis kit 
(Bio-rad, 170-8841) (Widowati et al. 2018; Afifah et al. 
2019; Widowati et al. 2019). Primer sequences were 
used can be seen at Table 1. 
2.3. Cytotoxic Assay
MCF7 and NK92 cells were seeded at a ratio 1:1 
onto transwell 24 well-plate (Corning, 3396). MCF7 
were seeded on the first day allowed to attach to the 
bottom chamber. Next day, NK92 induced by IL15 
(0, 5, 10 ng/ml) were seeded to the upper chamber. 
The plate was incubated for 24 hours at 37°C, 5% CO2. 
Hereinafter, the upper chamber and the medium 
were discarded. The cells were washed one time using 
PBS 1x. After that, 500 µl Presto Blue 1x (Invitrogen, 
A13262) were added to each well and incubated for 
1 hour at 37°C, 5% CO2. The solution was transferred 
to 96-well plate and the absorbance was read at 570 
and 600 nm using spectrophotometer (Multiskan GO, 
ThermoScientific) (Widowati et al. 2018; Widowati et 
al. 2019).
2.4. Apoptosis Analysis Assay by Flow 
Cytometry
MCF7 and NK92 cells were seeded at a ratio 1:1 
onto 6 well/plate (Corning, 3412). On the first day, 
MCF7 were seeded at the bottom chamber and 
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Table 1. Activator, inhibitor receptor genes of NK Cells, RT PCR protocols
Gene symbols
NKG2A
NKG2D
GAPDH
Primer sequence (5’ to 3’)
Upper strand:sense
Lower strand:antisense
5’-CCAGAGAAGCTCATTGTTGG-3’
5’-CCAATCCATGAGGATGGT-3’
5’-CTGGGAGATGAGTGAATTTCATA-3’
5’-GACTTCACCTTAAGTAAATC-3’
5’-GGGCTGCTTTTAACTCTGGT-3’
5’-TGGCAGGTTTTTCTAGACGG-3’
Product size 
(bp)
168 
417 
702 
40x
40x
40x
51
51
51
Annealing
(°C)
References
Gen Bank:AF461812.1
Gen Bank:AF461811.1
Sadeghi et al. 2015
Cycle
plates were incubated for 24 hours at 37°C, 5% CO2. 
On the next day, NK92 cells were added to the upper 
chamber. The NK92 cells were induced by IL15 (5 
ng/ml and 10 ng/ml). The uninduced NK92 cells and 
MCF7 without transwell were also done as a control. 
The plate was then incubated for 24 hours at 37°C, 5% 
CO2. Subsequently, MCF7 at the bottom chamber were 
collected and washed  two times by FACS buffer (2% 
FBS in PBS 1x). Pellets were resuspended in 100 µl FACS 
buffer and 5 µl Annexin V (BioLegend, Part 79998), 10 
µl PI (BioLegend, Part 79997) were added. The cells 
were incubated for 30 minutes in 4°C dark room. 
Following the 30 minutes incubation, samples were 
added 400 µl annexin V-binding buffer (BioLegend, 
640194) and immediately analyzed by flow cytometry 
(MACSQuant™ Analyzer 10, Miltenyi Biotec) (Widowati 
et al. 2018; Widowati et al. 2019).
2.5. Quantification of Granzyme-B Level
The quantitative determination of GzmB in the 
transwell-treatment, conditioned medium from NK 
cells from upper chamber and conditioned medium 
from MCF7 was performed using ELISA Kit Human 
Granyme-B (Human ELISA KIT, ElabSci E-EL-H1617) 
followed the manufactur protocol. Absorbance was 
read at 450 nm using spectrophotometer (Safta et al. 
2015; Widowati et al. 2018, 2020).
2.6. Determination of Apoptosis Gene 
Expression
MCF7 cells had been transwelled with induced 
NK92 cells (IL15 with various concentration 0, 5, 10 
ng/ml) for 24 h. Afterward, microscopic analysis was 
conducted under inverted phase-contrast microscope. 
Subsequently the MCF7 cells were collected to isolate 
the RNA. The RNA isolation of MCF7 was performed 
based on the protocol of RNA Isolation Kit (Bio-Rad, 
732-6820). The concentration and purity of RNA of 
each sample was determined at 260/280 nm. The 
cDNA synthesis was performed using cDNA synthesis 
kit (Bio-rad, 170-8841) (Widowati et al. 2018; Afifah 
et al. 2019; Widowati et al. 2019). Primer sequences 
can be seen at Table 2.
2.7. Statistical Analysis
All the data are presented as the mean ± standard 
deviation. The data were analyzed using one-way 
analysis of variance (ANOVA) followed by Tukey’s 
post-hoc test for multiple comparisons with p-values 
less than 0.05 were considered significant.
3. Results
3.1. Effect of IL15 toward NK Cell Characteristics 
To determine the effect of human recombinant IL15 
toward NK receptors, we evaluated the NK receptors 
including gene expression of NKG2D and NKG2A 
(Figure 1). The data showed that IL15 (5, 10 ng/ml) 
significantly up-regulated NKG2D, meanwhile IL15 did 
not significantly down-regulate NKG2A.
Based on the data (Figure 1) shows that IL15 
induced up-regulation of NKG2D gene expression, the 
highest NKG2D expression was IL15 (5 ng/ml) higher 
concentration of IL15 (10 ng/ml) lowered NKG2D 
expression. IL15 both concentrations (5, 10 ng/ml) 
didn’t affect NKG2A expression of NK cells. 
3.2. Cytotoxic Activity of IL15-Induced NK 
toward BC Cells
NK cells are involved in the elimination of tumor 
cells. To determine the effect of human recombinant 
IL15 on NK cells toward cytotoxic activity of BC cells. 
We determine the effect of IL15-induced NK toward 
MCF7 cells by transwell method. NK cells treated with 
IL15 at concentrations of 0, 5, 10 ng/ml (IL15-induced 
NK cells) against BC cell proliferation, we evaluated 
the inhibition of MCF7 proliferation (Figure 2).
Figure 2 shows that NK cells uninduced with IL15 
had cytotoxic activity against MCF7 cells approximatelly 
35.20% inhibitory growth cells. Both concentrations 5, 
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Table 2. Apoptotic primer for MCF7 cells, RT PCR protocols
Gene symbols
p53
bax
bcl2
β-Actin
Primer sequence (5’ to 3’)
Upper strand:sense
Lower strand:antisense
5’-AGAGTCTATAGGCCCACCCC-3’
5’-GCTCGACGCTAGGATCTGAC-3’
5’-TGCTTCAGGGTTTCATCCAG-3’
5’-GGCGGCAATCATCCTCTG-3’
5’-GGTCATGTGTGTGGAGAGCG-3’
5’-GGTGCCGGTTCAGGTACTCA-3’
5’-TCTGGCACCACACCTTCTACAATG-3’
5’-AGCACAGCCTGGATAGCAACG-3’
Product size 
(bp)
97 
169 
89 
166 
40x
40x
40x
40x
58
58
58
85
Annealing
(°C)
References
Behbahani 2014; 
Widowati et al. 2019
Wang et al. 2009; 
Widowati et al. 2019
Guan et al. 2018; 
Widowati et al. 2019
Han et al. 2018
Cycle
1.40
1.20
12.00
1.00
10.00
0.80
8.00
0.60
6.00
0.40 4.00
0.20 2.00
0.00
0 ng/ml 
IL15-NK
Figure 1. Effect IL15 inducer on NK cells toward NKG2A and NKG2D gene expression. The data are presented as histogram 
among treatments, this research was conducted in triplicate for each treatment. The asterisks symbol (*) presents 
significant difference between (inducing IL15 5 ng/ml, inducing IL15 10 ng/ml) and non inducing of NK cells 
based on Tukey HSD post hoc test (p<0.05). (a) The IL15 didn’t affect NKG2A gene expression. (b) The NKG2D 
expression of higher concentration (10 ng/ml IL15) was lower than 5 ng/ml IL15
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Figure 2. Effect of IL15 inducer on NK cells toward proliferation inhibition of MCF7 cells. The data are presented as 
histogram among treatments, this research was conducted in triplicate for each treatment. The asterisks symbol 
(*) presents significant difference between (inducing IL15 5 ng/ml, inducing IL15 10 ng/ml) and non inducing 
of NK cells based on Tukey HSD post hoc test (p<0.05). Figure 2 shows that IL15 activated NK cells to inhibit 
MCF7 cell proliferation and increased anticancer activity NK cells against proliferation of MCF7 cells. The higher 
concentration (10 ng/ml) of IL15 was not significant difference compared to lower concentration of IL15 (5 ng/
ml) against MCF7 cells proliferation
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10 ng/ml of IL15 induced NK cells to inhibit MCF7 cells 
proliferation about 65.60-70.29%.
3.3. Effect of IL15-Induced NK Cells toward 
Apoptosis of MCF7 Cells
 NK cells require effectors to activate NK cells; thus, 
this study was conducted to evaluate the effect of IL15 
toward apoptosis of MCF7 cells by transwell method. 
To determine the effect of human recombinant IL15 on 
NK cells toward apoptotic percentage of MCF7 cells, we 
evaluated apoptotic percentage of MCF7 cells (Figures 3). 
We used IL15 at levels of 0 (uninduced), 5 and 10 ng/ml. 
The data (Figure 3) show that IL15 increased apoptotic 
percentage of MCF7, the highest apoptotic potency was 
NK induced by 5 ng/ml, higher concentration of IL15 
(10 ng/ml) lower apoptotic percentage than NK induced 
by 5 ng/ml.
 Based on the apoptotic percentage of MCF7 cells were 
treated by IL15-induced NK cells using transwell method 
(Figure 3), shows that NK cells uninduced with IL15 
was very low apoptotic potency (3.98%), IL15 activated 
NK cells and increased apoptotic potency against MCF7 
cells, the best IL15 concentration was 5 ng/ml, higher 
concentration of IL15 significantly lowered apoptotic 
percentage of MCF7 cells.
3.4. Effect of IL15-Induced NK Cells toward 
Granzyme Level in Transwell of MCF7 and NK 
Cells
  We measured NK cells were activated using IL15 (0, 
5, 10 ng/ml). The cell ratios (MCF7: NK cells=1:1) were 
assessed for the ability to secrete GzmB. The effects 
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Figure 3. Effect IL15 inducer on NK cells toward apoptotic percentage of MCF7 cells. The data are presented as histogram 
among treatment, this research was conducted in triplicate for each treatment. The asterisks symbol (*) present 
significant differences among concentrations of IL15 inducer (0, 5, 10 ng/ml) compared to control (MCF7 non 
treatment) toward apoptotic percentage of MCF7
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(non treatment)
MCF 7+(5 ng/ml-NK)MCF 7+(0 ng/ml-NK) MCF 7+(10 ng/ml-NK)
HAYATI J Biosci                                                                                                                                                                       99
Vol. 27 No. 2, April 2020
190                                                                                                     Widowati W et al.
of IL15-induced NK (IL15-NK) transwelled with MCF7 
cells, which made NK released cytoplasmic granules 
(GzmB) can be seen in Figure 4.
 The GzmB level secreted by NK cells which co-
cultured with MCF7 cells using transwell method 
(Figure 5). NK cells uninduced by IL15 secreted GzmB 
in low level (77.06 pg/ml), inducing IL15 (5, 10 ng/ml) 
increased secretion of GzmB, the highest GzmB level 
was secreted by NK cells which induced by IL15 (5 ng/
Figure 4. Effect of IL15 inducer on NK cells toward GzmB 
level of transwell MCF7 and NK cells. The data 
are presented as histogram among treatment, 
this research was conducted in triplicate for 
each treatment. The asterisks symbol (*) present 
significant differences among concentrations of 
inducer IL15 (0, 5, 10 ng/ml) compared to control 
(MCF7 non treatment)  toward GzmB level
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qPCR. We measured the expression of proapoptotic 
genes, specifically p53, b-cell cll/lymphoma 2 (bcl-
2), bcl2-associated x protein (bax). The p53, bax 
and bcl2 genes expression of MCF7 can be seen at 
Figure 5.
 NK cells induced by IL15 significantly 
increased the apoptotic genes both low and high 
concentrations (5, 10 ng/ml) toward p53, bax genes 
expression (Figure 5a and 5b) but IL15-induced NK 
didn’t affect bcl2 expression (Figure 5c). The highest 
p53 expression was MCF7 treated with 5 ng/ml 
IL15-induced NK cells, the higher concentration 
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ml), meanwhile higher IL15 concentration (10 ng/ml) 
lowered GzmB level.
3.5. Effect IL15-Induced NK Cells toward 
Apoptotic and Antiapoptotic Genes 
Expression of MCF7
 This study was the continued-research to 
elucidate the apoptosis mechanism of IL15-induced 
NK cells toward MCF7 cells, in order to determine 
the apoptotic inducing activity of IL15-induced 
NK cells toward MCF cells by transwell assay, the 
expression of apoptotic genes was determined by 
Figure 5. Effect IL15 inducer on NK cells toward p53, bax and bcl2 gene expression of MCF7 cells. The data are presented as 
histogram among treatments, this research was conducted in triplicate for each treatment. The asterisks symbol 
(*) presents significant difference between (inducing IL15 5 ng/ml, inducing IL15 10 ng/ml) compred control 
(MCF7 non treatment) based on Tukey HSD post hoc test (p<0.05). Figure 5 shows that IL15 (5, 10 ng/ml) up-
regulated gene expression of p53 (Figure 5a), bax ( Figure 5b), but didnt affected bcl2 gene expression (Figure 5c)
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of IL15 (10 ng/ml) was significantly lower p53 
expression (Figure 5a). The bax gene expression of 
MCF7 cells treated with 10 ng/ml IL15-induced NK 
cells was unsignificantly difference compared to 5 
ng/ml IL15-induced NK cells.
3.6. Effect IL15-Induced NK Cells against 
MCF7 Cells Morphology
 This study was performed by investigating 
the effect of IL15-induced NK cells on viability, 
density, morphology of MCF7 cells (Figure 6). The 
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MCF7
A1 B1
B2A2
MCF7+NK cell 
(0 ng/ml IL15)
MCF7+NK cell 
(5 ng/ml IL15)
A3 B3
B4A4
MCF7+ NK cell 
(10 ng/ml IL15)
Figure 6. Morphological analysis using phase-contrast microscope at ×100 magnification (A1, A2, A3, A4) and x40 
magnification (B1, B2, B3, B4). Different concentration of IL15 as inducer for  NK cells decreased the survival rate 
of MCF7 cells
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result demonstrates that NK cells induced  dose-
dependent reduction in viability of MCF7 cells.
 Based on the morphological MCF7 cells treated 
with NK cells using transwell assay shows that 
NK cells lower the viability and density BC cells. 
The highest viability and density cells was MCF7 
(control), the lowest viability, density cells was 
MCF7 treated by IL15 (5 ng/ml) as NK cells inducer.
4. Discussion
 NK cell abnormalities in cancer patients 
such as imbalance of immune status, inclined to 
immunosuppression, decreased in NK cell numbers, 
decreased cytotoxicity, declined activiating receptor 
(NKG2D, NKG2C, NKp30, NKp46) and inclined 
inhibitory receptor (NKG2A, CD158, CD158a). 
Recently has been developed the immunotherapy 
using activated-NK cells (Mamessier et al. 2011). 
IL2, IL12, IL15, and IL18, applied systemically and for 
ex vivo activation and expansion of NK cells, have 
improved NK cell antitumor activity by increasing 
the expression of NK cell activating receptors and by 
inducing cytotoxic effector molecules (Konjevic et 
al. 2016). Cytokines such as interleukins (IL2) can be 
used to increase the anticancer potency of NK cells 
(Widowati et al. 2019). Various types of stimulation 
have been reported to enable NK cells to achieve their 
full effector potential, such as IL15, IL12, IL18, IL21 
(Lucas et al. 2007; Guia et al. 2008; Chaix et al. 2008; 
Brehm et al. 2011). Based on the result (Figure 1), IL15 
induced activating receptor NKG2D, this result was 
validated with previous research that IL2 and IL15 
induce the expression of KIRs and activating receptors 
(NKG2D and NKp44) on NK cell surface (Rham et al. 
2007; Boieri et al. 2017). This result was in line with 
previous research that metastatic melanoma (MM) 
patients exhibited decreased CD161 and NKG2D 
(Konjevi'c et al. 2009). NK cells treated with IL15 up-
regulated the expression of NK receptors, including 
Nkp30, Nkp46, NKG2C, and NKG2D (Szczepanski et 
al. 2010). IL15 didn’t decline the inhibitory receptor 
(NKG2A), this result was not consistent with previous 
research that IL15+IL12 was significantly decline 
the NKG2A of HIV-infected individuals (Parasa et al. 
2012).
 NK cells have been used in clinical studies in order 
to treat various malignancies (Harada et al. 2017), NK 
cells abnormalities in cancer patients such as low NK 
cells counts in PBMC, decreased cytotoxicity (Levy et al. 
2011). NK cells inhibited MCF7 cells proliferation, IL15 
activated NK cells to inhibit MCF7 cells proliferation, 
this result was consistent with previous research 
that NK cells control tumor growth and metastasis 
diffusion in vivo (Zamai et al. 2007). The low NK cell 
numbers in tumors due to their inefficient homing 
into malignant tissues (Levy et al. 2011). Decreasing 
NK cell numbers are observed in peripheral blood 
(PB) of cancer patients; therefore, NK cells decrease 
in tumor infiltrate (Levy et al. 2011). The activity 
and numbers of NK cells need to be enhanced for 
better efficacy (Mandal and Viswanathan 2002). 
NK cell infiltration in solid tumors was associated 
with a better prognosis (Villegas et al. 2002). IL-15 
is essential for NK cell survival, differentiation, and 
proliferation (Anton et al. 2015). Improving NK cells 
cytotoxicity used ILs (IL15, IL18), the result showed 
that ILs increased TNFα, IFNγ secretion by NK cells 
(Widowati et al. 2020)
 IL15 induces optimal production of IFN-γ from 
NK cells, subsequently induce apoptosis of the NK 
cells toward cancer cells (Ross and Caligiuri 1997; 
Widowati et al. 2020). The human MHC class I-negative 
of small cell lung cancer cell line (N592) genetically 
engineered to secrete IL-15, N592/IL-15, showed a 
reduced tumor growth rate (Orengo et al. 2003). IL15 
and IL12 induces optimal production of IFN-γ from 
NK cells (Ross and Caligiuri 1997). IFNγ inhibited BC 
proliferation (MCF7) with median inhibitory 0.34 
µg/ml (Widowati et al. 2016). IFNγ against MCF7 
cells exhibited that the cytokines decreased the cell 
viability in a dose dependent manner (Widowati et al. 
2016). 
 NK secrete GzmB, IL15-activated NK cells up-
regulated GzmB secretion. This result was validated 
previous research that activated NK cells released 
higher levels of IFN-γ, TNF-α, Prf1, and GzmB compared 
to non-induced NK cells. IL2, IL15, and IL18 increased 
the secretion of IFN-γ, TNF-α, Prf1, and GzmB by co-
culture cells (Widowati et al. 2020). IL15 in NK cell 
controls as well survival of mature NK cells in the 
periphery (Marçais et al. 2013; Widowati et al. 2020), 
mediated by up-regulation of anti-apoptotic bcl2 
family members and down regulation of apoptotic 
(Marçais et al. 2013). The production of TNF-α, IFN-γ, 
Prf1, GzmB increased when the ratio of NK cells and 
hWJMSCs was high (Widowati et al. 2019). NK cells 
activity were controlled by cytokine and ILs (IL2, IL12, 
IL15, IL18) (Domaica et al. 2012). NK cells eliminate 
malignantly transformed cells principally by releasing 
the contents of cytotoxic granules into the immune 
synapse formed with their target cell (Lieberman 
2003). The granule mediators of target cell lysis 
are serine proteases, known as Gzm, which induce 
programmed cell death (Safta et al. 2015; Harada et 
al. 2017). Cytotoxicity of NK cells is executed mainly 
through the granule exocytosis pathway by releasing 
Prf1 and GzmB into the immunological synapse after 
the conjugate formation with targets (Lieberman 
2003). Human GzmB preferentially induces target cell 
apoptosis, induces a rapid accumulation of the tumor-
suppressor protein p53 within target cells (Safta et 
al. 2015). Human GzmB-induced p53 accumulates 
on target cell mitochondria where it interacts with 
the prosurvival protein bcl2. This interaction allows 
the release of the proapoptotic protein bax from its 
inhibitory interaction with bcl2 (Safta et al. 2015). 
Several proteins that are involved in GzmB-induced 
apoptosis, including casp-9 and -3, bim, bid, bak, 
bax, and xiap. GzmB induced apoptosis cancer cells 
by involving induction of p53 tumor suppressor gene 
(Meslin et al. 2007).
 IL15  inhibit MCF7 proliferation, induced 
apoptotic BC cells, this result also supported by MCF7 
morphology, BC cells appear low density and viability. 
This result was supported by previous research that 
ILs (IL1, IL2, IL15) and CD28, serve as co-stimulatory 
factors, enhancing IFN-γ production by NK cells, as 
well as NK cell proliferation and cytotoxicity (Hunter 
et al. 1997; Cui et al. 2016). ILs (IL12, IL18) stimulate 
NK cell lines, increasing the secretion of IFN-γ (Wang 
et al. 2012). IL12 and IL18 are critical regulators that 
activate NK cells via the production of cytokines and 
direct lysis of target cells (Vivier et al. 2011). IL15 
activate, increase NK proliferation (Widowati et al. 
2020). Activated NK cells induce IFN-γ, TNF-α, Prf1, 
GzmB secretion and inhibit BC cells proliferation on 
co-cultured of MCF7 and NK cells (Widowati et al. 
2020).
 The proposed mechanism of our research which 
IL15 activated NK cells including increased NK cells 
number, up regulated activating receptor (NKG2D) 
but IL15 didn’t influnce inhibitor receptor (NKG2A), 
improved Prf, Gzm secretion. IL15-activated NK 
induced apoptosis of BC cells through increased 
p53, bax gene expression and inhibited BC cells 
proliferation. For the detail mechanism can be seen 
at Figure 7.
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Figure 7. Proposed mechanism of activated NK cells to inhibit and kill breast cancer cells. NK cells abnormalities in breast 
cancer patients. The imbalance of immune status, which defficient immunosurveillance including low NK cell 
number in PBMC, poor tumor inflitrate to cancer cells, decreased cytotoxicity, defective expression of activating 
receptor (NKG2D). IL15 activated NK cells to kill target cancer cells through: cytoplasmic granules release (Prf, 
GzmB), death receptor-induced apoptosis (TNFα), effector molecules production (IFNγ) and released antibody-
dependent cellular cytotoxicity (ADCC). p53, bax induced apoptotic BC cells
5. Conclusion
 IL15 improve, activate NK cells resulted in 
activating receptors (NKG2D), increasing GzmB 
secretion and cytotoxic activity on BC cells, inducing 
apoptotic genes bax, p53 expression and induce 
apoptotic cells on transwell assay.
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